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Systemic light chain (AL) amyloidosis is a rare disorder characterized by the tissue deposition of 
misfolded immunoglobulin light chains (Pepys, 2006).  One third of patients with cardiac AL 
amyloidosis present with a significant elevation of both N-terminal pro-brain natriuretic peptide 
(NT-proBNP) and troponin T (TnT) concentration (Mayo Stage III disease) which is associated 
with poor outcomes (Kyle and Gertz, 1995) (median survival of 9-12 months) and a high early 
mortality within the first few months of diagnosis (30-40%)(Wechalekar et al., 2016).  The main 
cause of this significant and early mortality is sudden cardiac death (SCD) – both ventricular 
tachyarrhythmias (Lin et al., 2010) and bradycardia (Sayed et al., 2015) have been observed as 
terminal events but the trigger remains unclear.  ICD implantation is a logical therapeutic 
intervention but efficacy, criteria for patient selection and long term survival benefit have yet to 
be determined.   
We report the UK experience with ICD implantation in a cohort of 15 patients with cardiac AL 
amyloidosis managed by a uniform supportive care, treatment and comprehensive assessment 
pathway from June 2010 to November 2015.  Organ involvement and hematological responses 
were defined as per the international amyloidosis consensus criteria. Chemotherapy treatment was 
undertaken as per the UK amyloidosis treatment guidelines (Wechalekar et al., 2015) with cardiac 
patients admitted for 48-72 hours of continuous ECG monitoring at the start of chemotherapy.  
Patients with serious recurrent ventricular arrhythmias (defined as non-sustained ventricular 
tachycardia (more than 4 beats of VT and lasting less than 30 seconds) on more than one occasion 
in the presence of syncope/presyncope or sustained VT) were considered for ICD implantation.  
All patients were treated in accordance with the Declaration of Helsinki and provided informed 
consent.  
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The baseline charactericts were: median age 51 years (range 37-80), median serum high-sensitivity 
TnT 60ng/L (range 22-326 ng/L), median NT-proBNP 5178 ng/L (range 2220 – 34,153); Mayo 
Staging II, IIIa and IIIb were 4/15, 8/15 and 3/15 respectively.  All patients had cardiac 
involvement with renal, liver and nerve involvement in 7/15 (47%%), 5/15 (33%) and 1/15 (7%) 
patients respectively.  4 (27%) patients gave a history of recurrent  syncope.  At presentation, five 
patients were receiving β-blocker therapy.  All patients received chemotherapy with front line 
Bortezomib or Thalidomide based regime.  
13 (87%) patients were in sinus rhythm. 2 (13%) had atrial fibrillation.  One patient had evidence 
of 1st degree atrio-ventricular conduction block.  Diastolic dysfunction was mild, moderate and 
severe in 2 (13%), 6 (40%) and 7 (47%), respectively.  Median global left ventricular strain was 
−9.5% (range −0.08 to −18.2%) and median left ventricular ejection fraction (LVEF) was 53% 
(range 40-65 %).  
Median time to ICD implantation was 13 days from  first presentation, median follow-up was 4.9 
months (range 1.35 – 66.12).  Fourteen patients (93%) underwent ICD implantation for primary 
prevention -  12 had non sustained VT and 2 sustained VT with spontaneous reversion. Only one 
patient underwent implantation for secondary prevention after ventricular fibrillation.  13/15 
(87%) of the patients were started on oral amiodarone after ICD implantation.  The remaining 2 
patients received beta blocker therapy (one of whom was intolerant of amiodarone,  the other was 
thyrotoxic).  After ICD implantation, NSVT was detected in 6 (40%) patients (five on amiodarone 
and one on beta blockers).   
Four patients had therapy from their ICD, three for ventricular arrhythmias and one patient had 
pacing for bradyarrhythmia.  Two out of these four patients have since died.  Overall, 13 out of 15 
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patients are alive with overall survival at 3, 6 and 12 months of  93%, 82% and 82% respectively.  
Of the patients who died, one had VF after 8 days of commencing treatment, successfully reverted 
to sinus rhythm after ICD shock but died ten day later for further intractable VF despite appropriate 
shocks.  The second patient had Mayo stage 3b disease, developed VF during her 2nd cycle of 
chemotherapy, was appropriately  shocked and remained in sinus rhythm but had refractory clonal 
disease and died over 3 months later with end stage heart failure. 
Although survival in systemic AL amyloidosis has substantially improved, early mortality has 
essentially remained unchanged with no clear consensus on either the immediate or long term 
options for prevention of SCD.  ICD implantation is a potentially attractive option.  A quarter of 
the patients in the current cohort received appropriate therapy from the ICD, an additional third of 
patients had NSVT which did not need ICD intervention and a good overall survival of 82% at 12 
months.  In the immediate short term, ICD was life-saving in all cases who received appropriate 
therapy but only two out of the four patients achieved longer term survival. (Venner et al., 2012). 
The German amyloidosis group failed to demonstrate any benefit from ICD with a high mortality 
of 47% - including appropriate shock therapy in only 2 patients (11%) and only one patient 
surviving post therapy (Kristen et al., 2008).  Contrarily, two other studies from the US, reported 
appropriate shock therapy in just over a third the patients (Varr et al., 2014, Lin et al., 2013) - data 
similar to our current results.  Limitations of our study include patient selection, small sample size 
and the majority of our patients were on routine amiodarone after ICD implantation. 
Table 1 summarises the data available (counting our cohort) in 82 patients reported to date.  The 
majority of ICD implantation was for primary prevention and 28% of patients actually required 
device therapy.  Importantly, nearly three quarters of all patients who had therapy from their ICD 
survived immediately following therapy – potentially allowing time for delivery of chemotherapy 
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to reduce the light chain burden.  Longer term survival (determined in AL by amyloid burden, 
organ involvement, haematolgic response and treatment toxicity) was only 50% and was probably 
not impacted directly by ICD.  We propose an algorithm for consideration of ICD implantation in 
patients with AL amyloidosis (Figure 1) – to consider ICD implantation for patients with moderate 
cardiac involvement (Stage II and IIIa) and focus arrhytmima prevention in patients with the most 
advanced disease (Mayo stage IIIb) .   
In conclusion, ICD implantation, in selected patients with AL amylodiosis, deliver appropriate 
therapy and are life saving in the short term but long term survival benefit remain unclear.  Formal 
prospective studies of device therapy in AL amyloidosis are urgently needed.   
 
Acknowledgements: 
We thank our many physician colleagues for referring and caring for the patients as well as the 
staff at the National Amyloidosis Centre.  Core support for the Wolfson Drug Discovery Unit, 
Centre for Amyloidosis and Acute Phase Proteins is provided by NHS England, the UK National 
Institute for Health Research Biomedical Research Centre and Unit Funding Scheme. 
 
Author Contributions: 
TR, CW and ADW conceived the manuscript. CW, HJL, MF, SS, SM, FK, RK, JT, TY, JDG and 
ADW were responsible for care and follow up of patients during the study.  All authors reviewed 
the final manuscript. 
7 
 
7 
 
References: 
 
Kristen, A. V., Dengler, T. J., Hegenbart, U., Schonland, S. O., Goldschmidt, H., Sack, F. U., 
Voss, F., Becker, R., Katus, H. A. & Bauer, A. (2008) Prophylactic implantation of 
cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for 
sudden cardiac death. Heart Rhythm, 5, 235-240. 
Kyle, R. A. & Gertz, M. A. (1995) Primary systemic amyloidosis: clinical and laboratory 
features in 474 cases. Seminars in Hematology, 32 (1), 45-59. 
Lin, G., Dispenzieri, A. & Brady, P. A. (2010) Successful termination of a ventricular arrhythmia 
by implantable cardioverter defibrillator therapy in a patient with cardiac amyloidosis: 
insight into mechanisms of sudden death. European Heart Journal, 31, 1538. 
Lin, G., Dispenzieri, A., Kyle, R., Grogan, M. & Brady, P. A. (2013) Implantable cardioverter 
defibrillators in patients with cardiac amyloidosis. Journal of Cardiovascular 
Electrophysiology, 24, 793-798. 
Pepys, M. B. (2006) Amyloidosis. Annual Review of Medicine, 57, 223-241. 
Sayed, R. H., Rogers, D., Khan, F., Wechalekar, A. D., Lachmann, H. J., Fontana, M., 
Mahmood, S., Sachchithanantham, S., Patel, K., Hawkins, P. N., Whelan, C. J. & 
Gillmore, J. D. (2015) A study of implanted cardiac rhythm recorders in advanced 
cardiac AL amyloidosis. European Heart Journal, 36, 1098-1105. 
Varr, B. C., Zarafshar, S., Coakley, T., Liedtke, M., Lafayette, R. A., Arai, S., Schrier, S. L. & 
Witteles, R. M. (2014) Implantable cardioverter-defibrillator placement in patients with 
cardiac amyloidosis. Heart Rhythm, 11, 158-162. 
Venner, C. P., Lane, T., Foard, D., Rannigan, L., Gibbs, S. D., Pinney, J. H., Whelan, C. J., 
Lachmann, H. J., Gillmore, J. D., Hawkins, P. N. & Wechalekar, A. D. (2012) 
8 
 
8 
 
Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is 
associated with high clonal response rates and prolonged progression-free survival. 
Blood, 119, 4387-4390. 
Wechalekar, A. D., Gillmore, J. D., Bird, J., Cavenagh, J., Hawkins, S., Kazmi, M., Lachmann, 
H. J., Hawkins, P. N. & Pratt, G. (2015) Guidelines on the management of AL 
amyloidosis. British Journal of Haematology, 168, 186-206. 
Wechalekar, A. D., Gillmore, J. D. & Hawkins, P. N. (2016) Systemic amyloidosis. Lancet, 387, 
2641-54. 
  
9 
 
9 
 
Figure Legends 
 
Figure 1 
Approach to ICD implantation in cardiac AL amyloidosis. 
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Table 1. Analysis of studies to date on ICD implantation in patients with cardiac amyloidosis. 
 
Study/Date Device Patients 
with AL 
Primary/ 
secondary 
prevention 
Appropriate 
therapy from 
device (%) 
Survival 
post 
therapy 
(%) 
Survival 
during follow 
up of 
patients who 
received 
appropriate 
therapy (%) 
Overall 
survival 
for cohort 
Varr et al 
(2014) 
ICD 15 11 Primary 
prevention 
4 Secondary 
prevention 
5/15 (33%) 4/5 
(80%) 
1/4 (25%)  
Lin G et al 
(2013) 
ICD 33 25 Primary 
prevention 
8 Secondary 
prevention 
12/33 (36%)   10/33 
(30%) 
Kristen et al 
(2008) 
ICD 19 19 Primary 
prevention 
2/19 (11%) 1/2 
(50%) 
1/2 (50%) 10/19 
(53%) 
Current 
series 
ICD 15 14 Primary 
prevention 
1 Secondary 
prevention 
4/15 (27%) 3/4 
(75%) 
2/4 (50%) 13/15 
(87%) 
ALL 
Studies 
ICD 82 69 Primary 
prevention 
13 Secondary 
prevention 
23/82 (28%) 8/11 
(73%) 
4/10 (40%) 33/67 
(49%) 
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